ClinicalTrials.gg
CompletedNCT02474355ASTRISUpdated Nov 11, 2021Results posted

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

A Phase 3 interventional study of T790M+ Testing and Baseline Visit Blood & Urine Testing in Lung Cancer, sponsored by AstraZeneca. Completed at 201 sites in 16 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-11-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,017
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing osimertinib in Lung Neoplasms — 10 open to participants now, 18 under way, 2 of them phase 3. osimertinib · Lung Neoplasms.

Enrollment
2nd of 30
3,017 · median 52
Started
2015
with 3 others
Phase 3
4 of 30
1 open now
Registered
2nd of 30
by date
Lead sponsor
10 of 30
AstraZeneca

Among the 30 studies testing osimertinib in Lung Neoplasms, this one is the 2nd largest by enrollment, is one of 4 that started in 2015, is one of 4 in phase 3, and was the 2nd registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 30 studies testing osimertinib in Lung Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing osimertinib in Lung Neoplasms, or all of them as a file.
02

Study summary

The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.

Read the detailed description

Objective: The primary objective of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.

Study site(s) and number of patients planned: Approximately 1500 patients will be recruited in Europe. The recruitment will be increased beyond that as the study will expand in other regions of the world (America, Asia).

Study Design This will be an open-label, single-arm, multinational, multicenter, real world treatment study.

Target patient population: Adult patients (fulfilling the definition of "age of majority" per local regulations) with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC with confirmed T790M mutation, who have received prior EGFR-TKI therapy.

Investigational product (IP), dosage, and mode of administration: AZD9291 is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. AZD9291 will be administered orally as one 80 mg tablet once a day.

Duration of IP administration: Patients may continue to receive AZD9291 as long as they continue to show clinical benefit, as judged by the investigator, and in the absence of discontinuation criteria). The study will be closed in each participating country as soon as possible following national reimbursement of AZD9291 in that country (up to a max of 90 days post reimbursement). Enrolment will be closed within 6 months after market license approval in that country or at national reimbursement, whichever is sooner. Patients withdrawing from the treatment prior to national reimbursement will be followed up as part of this study. Patients on treatment will receive commercial supply until documented disease progression as per investigator assessment.

In the event that national reimbursement should not be granted following a reasonable time after market license approval in the country, the study will be closed in a maximum period of 18 months after the last patient is enrolled in that country. If applicable, timelines for conversion to commercial drug will be agreed with local bodies which may include regulatory agencies, ethics committees, and institutions. Patient will be followed until death or lost to follow-up.

Study measures: Data collected will include patient demographics, information needed to determine patient eligibility (including medical history, past and current disease characteristics, and tumor EGFR mutational status), AZD9291 exposure, investigator-reported efficacy (including tumor response and disease progression), overall survival (OS), and safety (including serious adverse events [SAEs], adverse events leading to dose modification, and adverse events of special interest [interstitial lung disease/pneumonitis-like events, and QTc prolongation events]).

Statistical methods: All data will be presented for the overall full analysis/evaluable set, and also by cohorts defined by number and type of previous treatment lines for the advanced disease. Descriptive statistics will be used for all variables, as appropriate. Continuous variables will be summarised by the number of observations, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarised by frequency counts and percentages for each category. OS and PFS will be summarized using Kaplan-Meier estimates of the median time to death or censoring and quartiles together with their 95% confidence intervals.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • NSCLC
  • EGFRm
  • T790M
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated written by the patient or legally acceptable representative prior to any study-specific procedures
  2. Adults (according to each country regulations for age of majority)
  3. Locally advanced (stage IIIB) or (stage IV) EGFRm NSCLC, not amenable to curative surgery or radiotherapy, with confirmation of the presence of the T790M mutation
  4. Prior therapy with an EGFR-TKI. Patients may have also received additional
  5. World Health Organization (WHO) performance status 0-2
  6. Adequate bone marrow reserve and organ function as demonstrated by complete blood count, biochemistry in blood and urine at baseline (please refer to IB for guidance)
  7. recording at baseline showing absence of any cardiac abnormality as per exclusion criterion #6
  8. Female patients of must be using adequate measures, must not be breast feeding, and must have a negative pregnancy test prior to start of dosing. Otherwise, they must have evidence of nonchildbearing potential
  9. Male patients must be willing to use barrier contraception, i.e., condoms

Exclusion criteria

Exclusion Criteria:

  1. Previous (within 6 months) or current treatment with AZD9291
  2. Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of AZD9291) any treatment known to be potent inhibitors or inducers of cytochrome P450 (CYP) 3A4
  3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, active infection including , , and , or significantly impaired bone marrow reserve or organ function, including hepatic and renal impairment, which in the investigator's opinion would significantly alter the risk/benefit balance.
  4. Patient with symptomatic central nervous system (CNS) who is neurologically unstable or has required increasing doses of to manage CNS symptoms within the 2 weeks prior to start AZD9291 administration;
  5. Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
  6. Any of the following cardiac criteria:

    1. Mean resting interval (QTcF) > 470 ms using Fredericia's formula :
    2. Any abnormalities in rhythm, conduction or morphology of resting (e.g., complete left bundle branch block, third degree heart block, second degree heart block)
    3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
  7. Any unresolved toxicity from prior therapy > grade 3 at the time of starting treatment
  8. History of to of AZD9291 or to drugs with a similar chemical structure or class to AZD9291
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3,017 participants (actual)

Study arms

  • Experimental
    AZD9291

    Single arm of AZD9291, starting dose of 80mg

    Procedure: T790M+ Testing · Procedure: Baseline Visit Blood & Urine Testing · Procedure: Baseline ECG · Procedure: Visual Slit-Lamp Testing · Drug: AZD9291 Dosing

Interventions

  • ProcedureT790M+ Testing

    If a previous lab report is unavailable, the patient will need to have T790M+ testing.

  • ProcedureBaseline Visit Blood & Urine Testing

    Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria

  • ProcedureBaseline ECG

    ECG to ensure absence of any cardiac abnormality

  • ProcedureVisual Slit-Lamp Testing

    Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms

  • Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time, in months from the date of first dose of Osimertinib until death due to any cause, or at last documented contact with participant status "alive" (in this study any participants alive at study discontinuation, or lost to follow-up was considered being censored at study discontinuation date or at the last known date participant was alive). OS was summarized using a Kaplan-Meier (KM) estimate of the median time to death or censoring together with their 95% confidence intervals.

    Time frame: From the date of first dose of Osimertinib until the date of death (due to any cause) or last participant contact [up to 43 months]

  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Safety assessment of Osimertinib was analyzed by evaluating AEs and SAEs.

    Time frame: From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]

Secondary outcomes

  1. Progression Free Survival

    PFS was defined as the time, in months from first dose of AZD9291/ost/study drug/ study treatment until the date of disease progression or death in the absence of progression. Participants who had not progressed or died at study discontinuation were censored at the time of the latest date of disease assessment. PFS was summarized using KM estimates of the median time to progression or death with their 95% confidence intervals.

    Time frame: From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]

  2. Time to Treatment Discontinuation (TTD)

    TTD or death was assessed as a supportive summary to PFS and defined as the time from the date of the first dose of osimertinib in the study until the date of osimertinib discontinuation or death, regardless of the reason for discontinuation. TTD was summarized using KM estimates of the median times to progression or death or treatment discontinuation.

    Time frame: From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]

  3. Response Rate (RR)

    RR was defined as the number (%) of participants with a best response (by Investigator assessment) of 'responding', regardless of the method of evaluation, and was based on a subset of the full analysis set consisting of subjects with at least one documented response assessment. RR was summarised together with the 95% CI.

    Time frame: From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]

07

Results

Posted Oct 25, 2021
Limitations and caveats
Participants alive at the time of national reimbursement or site closure were no longer followed for survival and therefore prematurely censored for the OS, PFS, and TTD analysis, leading to less mature data. As the timing of reimbursement and study closure differed between countries, duration of follow-up between sites and countries differed.

Participant flow

Participants who met all the inclusion and none of the exclusion criteria received treatment in a total of 209 centres in 16 countries. The study started on 18 September 2015 and primary completion date was 18 April 2019.

Participant flow — Overall Study
MilestoneOsimertinib
Started3014
Completed1386
Not completed1628
Withdrew: Other43
Withdrew: Eligibility criteria not fulfilled2
Withdrew: Lost to follow-up98
Withdrew: Withdrawal by subject124
Withdrew: Death1361

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time, in months from the date of first dose of Osimertinib until death due to any cause, or at last documented contact with participant status "alive" (in this study any participants alive at study discontinuation, or lost to follow-up was considered being censored at study discontinuation date or at the last known date participant was alive). OS was summarized using a Kaplan-Meier (KM) estimate of the median time to death or censoring together with their 95% confidence intervals.

Time frame:
From the date of first dose of Osimertinib until the date of death (due to any cause) or last participant contact [up to 43 months]
Reported as:
Median · Months
Overall Survival (OS)
MonthsOsimertinib
Overall Survival (OS)22.8 (21.6 to 23.8)
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Safety assessment of Osimertinib was analyzed by evaluating AEs and SAEs.

Time frame:
From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsOsimertinib
AE of special interest (AESI) or SAE923
AESI or SAE a causally related to Osimertinib338
AE leading to dose modification414
AE leading to discontinuation191
AESI113
AESI causally related to Osimertinib89
SAE657
SAE causally related to Osimertinib95
AE leading to death152
AE leading to death causally related to Osimertinib19
SecondaryProgression Free Survival

PFS was defined as the time, in months from first dose of AZD9291/ost/study drug/ study treatment until the date of disease progression or death in the absence of progression. Participants who had not progressed or died at study discontinuation were censored at the time of the latest date of disease assessment. PFS was summarized using KM estimates of the median time to progression or death with their 95% confidence intervals.

Time frame:
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Reported as:
Median · Months
Progression Free Survival
MonthsOsimertinib
Progression Free Survival11.1 (11.0 to 12.0)
SecondaryTime to Treatment Discontinuation (TTD)

TTD or death was assessed as a supportive summary to PFS and defined as the time from the date of the first dose of osimertinib in the study until the date of osimertinib discontinuation or death, regardless of the reason for discontinuation. TTD was summarized using KM estimates of the median times to progression or death or treatment discontinuation.

Time frame:
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Reported as:
Median · Months
Time to Treatment Discontinuation (TTD)
MonthsOsimertinib
Time to Treatment Discontinuation (TTD)13.5 (12.6 to 13.9)
SecondaryResponse Rate (RR)

RR was defined as the number (%) of participants with a best response (by Investigator assessment) of 'responding', regardless of the method of evaluation, and was based on a subset of the full analysis set consisting of subjects with at least one documented response assessment. RR was summarised together with the 95% CI.

Time frame:
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Reported as:
Number · Percentage of participants
Response Rate (RR)
Percentage of participantsOsimertinib
Response Rate (RR)57.3 (55.5 to 59.2)

Adverse events

Collected over From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osimertinib1,361/3,014 (45.2%)657/3,014 (21.8%)380/3,014 (12.6%)
Most frequent serious events
Showing 10 of 325
Most frequent serious events
EventOsimertinib
PneumoniaInfections and infestations74/3014
Pulmonary embolismRespiratory, thoracic and mediastinal disorders49/3014
DeathGeneral disorders34/3014
Cerebral infarctionNervous system disorders22/3014
Pleural effusionRespiratory, thoracic and mediastinal disorders20/3014
Deep vein thrombosisVascular disorders17/3014
DyspnoeaRespiratory, thoracic and mediastinal disorders15/3014
VomitingGastrointestinal disorders13/3014
DiarrhoeaGastrointestinal disorders12/3014
PyrexiaGeneral disorders12/3014
Most frequent other events
Showing 10 of 159
Most frequent other events
EventOsimertinib
Electrocardiogram QT prolongedInvestigations88/3014
DiarrhoeaGastrointestinal disorders30/3014
ThrombocytopeniaBlood and lymphatic system disorders20/3014
Platelet count decreasedInvestigations17/3014
NeutropeniaBlood and lymphatic system disorders16/3014
PneumonitisRespiratory, thoracic and mediastinal disorders13/3014
NauseaGastrointestinal disorders11/3014
ParonychiaInfections and infestations11/3014
VomitingGastrointestinal disorders10/3014
Aspartate aminotransferase increasedInvestigations10/3014

Baseline characteristics

The full analysis set included all participants who received at least one dose of study treatment.

Age, Categorical
Age, Categorical(Participants)Osimertinib
<=18 years0
Between 18 and 65 years1798
>=65 years1216
Age, Continuous
Age, Continuous(Years)Osimertinib
Mean61.7 ± 10.91
Sex: Female, Male
Sex: Female, Male(Participants)Osimertinib
Female1927
Male1087
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Osimertinib
American Indian or Alaska Native0
Asian2085
Native Hawaiian or Other Pacific Islander0
Black or African American21
White897
More than one race0
Unknown or Not Reported11
Country
Country(Participants)Osimertinib
Argentina30
Australia31
Austria46
Belgium31
Brazil88
Canada99
China1350
Denmark6
Ireland10
Italy510
Saudi Arabia3
South Korea466
Spain131
Sweden7
Taiwan188
United Kingdom18
08

Study locations

201 sites
  • Research Site
    Buenos Aires, C1025ABI, Argentina
  • Research Site
    Buenos Aires, C1431FWO, Argentina
  • Research Site
    Caba, C1426ANZ, Argentina
  • Research Site
    Bedford Park, 5042, Australia
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Kurralta Park, 5037, Australia
  • Research Site
    Randwick, 2031, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Wien, 1140, Austria
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30380-472, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Ijui, 98700-000, Brazil
  • Research Site
    Itajai, 88310-110, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    Salvador, 40170-110, Brazil
  • Research Site
    Salvador, 41950-640, Brazil
  • Research Site
    Sao Paulo, 01221-020, Brazil
  • Research Site
    Sao Paulo, 01246-000, Brazil
  • Research Site
    Sao Paulo, 01509-900, Brazil
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Burnaby, British Columbia V5G 2X6, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    North York, Ontario M2K 1E1, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Quebec, G1V 4G5, Canada
  • Research Site
    Regina, Saskatchewan, S4T 7T1, Canada
  • Research Site
    Beijing, 100020, China
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100048, China
  • Research Site
    Beijing, 100053, China
  • Research Site
    Beijing, 100071, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Beijing, 100853, China
  • Research Site
    Beijing, 101149, China
  • Research Site
    Changchun, 130012, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410003, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400037, China
  • Research Site
    ChongQing, 400038, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Dalian, 116011, China
  • Research Site
    Fuzhou, 350009, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Fuzhou, 350025, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    GuangZhou, 510515, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hohhot, 010017, China
  • Research Site
    Ji Nan, 2501117, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210002, China
  • Research Site
    Nanjing, 210006, China
  • Research Site
    Nanjing, 210008, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Nantong, 226361, China
  • Research Site
    Qingdao, 266071, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Shenzhen, 518020, China
  • Research Site
    Shijiahzhuang, 050011, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Urumqi, 830000, China
  • Research Site
    Urumqi, 830054, China
  • Research Site
    Urumqi, 831118, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430071, China

Showing the first 100 of 201 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Leighl NB, Kamel-Reid S, Cheema PK, Laskin J, Karsan A, Zhang T, Stockley T, Barnes TA, Tudor RA, Liu G, Owen S, Rothenstein J, Burkes RL, Iqbal M, Spatz A, van Kempen LC, Izevbaye I, Laurence D, Le LW, Tsao MS. Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. JCO Precis Oncol. 2020 Nov;4:520-533. doi: 10.1200/PO.19.00335. PubMed 35050743 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Apr 2019, 43 months.

Results were first posted in Oct 2021, 2 years 6 months after primary completion. A results delay was requested in Apr 2019.

Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 43 months is above that.

Counting every sponsor, half of 128 studies reached it within 44 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2015
First posted
Jun 17, 2015
StartActual
Sep 18, 2015
Primary completionActual
Apr 18, 2019
CompletionActual
Apr 18, 2019
Results delay requested
Apr 19, 2019
Results first posted
Oct 25, 2021
Last update
Nov 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02474355
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jun 17, 2015
Start date
Sep 18, 2015
Primary completion
Apr 18, 2019
Completion
Apr 18, 2019
Results posted
Oct 25, 2021
Last update
Nov 11, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion